Matches in Nanopublications for { ?s ?p "[Using a diabody derived from a monoclonal antibody (12G4) directed against the human anti-M�llerian hormone receptor, a biomarker of ovarian cancers for which therapeutic antibodies are already undergoing clinical trials, we describe here a new diabody refolding protocol with various reducing conditions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP219113.RALj1VqlKSyCTQgB8RX9SMCKkiQY8yIkKrwVlvh3vgsbA130_assertion description "[Using a diabody derived from a monoclonal antibody (12G4) directed against the human anti-M�llerian hormone receptor, a biomarker of ovarian cancers for which therapeutic antibodies are already undergoing clinical trials, we describe here a new diabody refolding protocol with various reducing conditions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP219113.RALj1VqlKSyCTQgB8RX9SMCKkiQY8yIkKrwVlvh3vgsbA130_provenance.
- NP691787.RAjENX4QDDkqua5E6SUE0i6_KS6_KiIpNqnh7O9eTcADU130_assertion description "[Using a diabody derived from a monoclonal antibody (12G4) directed against the human anti-M�llerian hormone receptor, a biomarker of ovarian cancers for which therapeutic antibodies are already undergoing clinical trials, we describe here a new diabody refolding protocol with various reducing conditions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP691787.RAjENX4QDDkqua5E6SUE0i6_KS6_KiIpNqnh7O9eTcADU130_provenance.
- NP237370.RAQ9Wg-e6rhsmcRSy0aZNaqxH6dIOVNNn_rEUZ0TM94FU130_assertion description "[Using a diabody derived from a monoclonal antibody (12G4) directed against the human anti-M�llerian hormone receptor, a biomarker of ovarian cancers for which therapeutic antibodies are already undergoing clinical trials, we describe here a new diabody refolding protocol with various reducing conditions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP237370.RAQ9Wg-e6rhsmcRSy0aZNaqxH6dIOVNNn_rEUZ0TM94FU130_provenance.
- NP237507.RAAy2Yu48ALEpp1J-gbuVJlTDdhb1OzRKp6aTBj363Tso130_assertion description "[Using a diabody derived from a monoclonal antibody (12G4) directed against the human anti-M�llerian hormone receptor, a biomarker of ovarian cancers for which therapeutic antibodies are already undergoing clinical trials, we describe here a new diabody refolding protocol with various reducing conditions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP237507.RAAy2Yu48ALEpp1J-gbuVJlTDdhb1OzRKp6aTBj363Tso130_provenance.
- NP1006881.RAzxQEgWBJJIanO0AE90vMVHBy7c9YkaCSPLZWsTkR6kg130_assertion description "[Using a diabody derived from a monoclonal antibody (12G4) directed against the human anti-M�llerian hormone receptor, a biomarker of ovarian cancers for which therapeutic antibodies are already undergoing clinical trials, we describe here a new diabody refolding protocol with various reducing conditions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1006881.RAzxQEgWBJJIanO0AE90vMVHBy7c9YkaCSPLZWsTkR6kg130_provenance.
- NP1006883.RA9cEEyReTmO54Kfziu_C-A3wF5BmMTdGSODZwyL694hk130_assertion description "[Using a diabody derived from a monoclonal antibody (12G4) directed against the human anti-M�llerian hormone receptor, a biomarker of ovarian cancers for which therapeutic antibodies are already undergoing clinical trials, we describe here a new diabody refolding protocol with various reducing conditions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1006883.RA9cEEyReTmO54Kfziu_C-A3wF5BmMTdGSODZwyL694hk130_provenance.